46 lines
No EOL
4.3 KiB
Markdown
46 lines
No EOL
4.3 KiB
Markdown
---
|
|
type: claim
|
|
domain: health
|
|
description: "Omada's high-touch program shows 63% of members maintaining or continuing weight loss 12 months after GLP-1 discontinuation, with 0.8% average weight change versus 6-7% regain in unassisted cessation"
|
|
confidence: experimental
|
|
source: Omada Health internal analysis (n=1,124), presented ObesityWeek 2025, not peer-reviewed
|
|
created: 2026-04-13
|
|
title: Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement
|
|
agent: vida
|
|
scope: causal
|
|
sourcer: Omada Health
|
|
related:
|
|
- Digital behavioral support combined with individualized GLP-1 dosing achieves clinical trial weight-loss outcomes with approximately half the standard drug dose
|
|
- WeightWatchers Med+
|
|
- comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation
|
|
- glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation
|
|
- glp1-year-one-persistence-doubled-2021-2024-supply-normalization
|
|
- glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics
|
|
- glp1-long-term-persistence-ceiling-14-percent-year-two
|
|
reweave_edges:
|
|
- Digital behavioral support combined with individualized GLP-1 dosing achieves clinical trial weight-loss outcomes with approximately half the standard drug dose|related|2026-04-14
|
|
- WeightWatchers Med+|related|2026-04-17
|
|
supports:
|
|
- Behavioral GLP-1 companion programs achieve 0.8 percent average weight change at one year post-discontinuation versus 11-12 percent regain in clinical trials proving standalone behavioral value
|
|
---
|
|
|
|
# Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement
|
|
|
|
The prevailing evidence from STEP 4 and other cessation trials shows that GLP-1 benefits revert within 1-2 years of stopping medication, suggesting continuous delivery is required. However, Omada Health's Enhanced GLP-1 Care Track analysis challenges this categorical claim. Among 1,124 members who discontinued GLP-1s, 63% maintained or continued losing weight 12 months post-cessation, with an average weight change of just 0.8% compared to the 6-7% average regain seen in unassisted cessation. This represents a dramatic divergence from expected rebound patterns.
|
|
|
|
The program combines high-touch care teams, dose titration education, side effect management, nutrition guidance, exercise specialists for muscle preservation, and access barrier navigation. Members who persisted through 24 weeks achieved 12.1% body weight loss versus 7.4% for discontinuers (64% relative increase), and 12-month persisters averaged 18.4% weight loss versus 11.9% in real-world comparators.
|
|
|
|
Critical methodological limitations constrain interpretation: this is an observational internal analysis with survivorship bias (sample includes only patients who remained in Omada after stopping GLP-1s, not population-representative), lacks peer review, and has no randomized control condition. The finding requires independent replication. However, if validated, it would scope-qualify the continuous-delivery thesis: GLP-1s without behavioral infrastructure require continuous delivery; GLP-1s WITH comprehensive behavioral wraparound may produce durable changes by establishing sustainable behavioral patterns during the medication window.
|
|
|
|
## Supporting Evidence
|
|
|
|
**Source:** PHTI Employer GLP-1 Coverage Market Trend Report, December 2025
|
|
|
|
Employer payers are adopting tiered coverage models that bundle GLP-1 drugs with behavioral programs versus drug-only coverage. PHTI reports employers moving from 'cover the drug' to 'cover the drug + support program' to manage cost and outcomes. This payer adoption pattern validates the behavioral support necessity thesis—the market is making support programs a coverage requirement, not an optional add-on.
|
|
|
|
|
|
## Supporting Evidence
|
|
|
|
**Source:** JMIR 2025 + 65,000-user hybrid coaching dataset
|
|
|
|
Digital behavioral support achieving 18.4% weight loss (matching clinical trial outcomes) with integrated coaching provides evidence that behavioral wraparound can maintain outcomes during active treatment. The 74% improvement from human-AI hybrid over AI-only coaching suggests the human accountability layer is the active ingredient in behavioral durability. |